ClinicalTrials.Veeva

Menu

Prophylactic Antibiotics in Endoscopic Secondary Prevention of Gastroesophageal Variceal Bleeding

Zhejiang University logo

Zhejiang University

Status

Active, not recruiting

Conditions

Hypertension, Portal
Cirrhosis, Liver
Variceal Hemorrhage

Treatments

Drug: Prophylactic Antibiotics
Other: No use of prophylactic antibiotics

Study type

Interventional

Funder types

Other

Identifiers

NCT06437964
2024-0629

Details and patient eligibility

About

Whether prophylactic antibiotics should be administered in the endoscopic secondary prevention of GVB or not is unclear. In this non-inferiority trial, we are aimed to evaluate whether prophylactic antibiotics are essential in the endoscopic secondary prevention of cirrhotic patients with gastroesophageal variceal bleeding.

Full description

Prophylactic antibiotics like third-generation cephalosporin is recommended for acute gastroesophageal variceal bleeding (GVB). Endoscopic sequential therapy is an option in the secondary prevention of acute gastroesophageal variceal bleeding (GVB). However, the value of prophylactic antibiotics in the endoscopic secondary prevention of GVB is still unclear. It's assumed that the procedure of needle puncture under endoscopy will cause iatrogenic variceal bleeding. Besides, the surface of intraluminal varices is nonsterile, and injection of sclerosing agent or tissue adhesive will put patients at a risk of bacteremia. As a result, it's rational to use antibiotics prophylactically in the endoscopic sequential therapy of GVB. While giving antibiotics in all patients might cause abuse of antibiotics. In clinical practice now, the prophylactic administration of antibiotics is quite subjective. We observe that quite a lot of cirrhotic patients had no infection after endoscopic secondary prevention for gastroesophageal variceal bleeding, even they have not been administered prophylactic antibiotics. In this non-inferiority trial, we are aimed to evaluate whether no value of prophylactic antibiotics will increase the postoperative infection or not, in the endoscopic secondary prevention of cirrhotic patients with gastroesophageal variceal bleeding.

Enrollment

226 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Cirrhotic patients having a history of gastroesophageal variceal bleeding are readmitted for endoscopic secondary prevention.

Exclusion criteria

  1. Age <18, or ≥81.
  2. The patient is unwilling to sign the informed consent form.
  3. Allergy to cephalosporin.
  4. Have granulocyte deficiency (neutrophil count ≤ 0.5 * 10 ^ 9/L, or white blood cell count ≤ 1.0 * 10 ^ 9/L) before the endoscopic operation.
  5. Already have infection or fever (body temperature > 37.5 ℃) before signing the informed consent form.

Withdraw Criteria:

  1. The patient turned back after signing the consent, and before the endoscopic operation.
  2. Have fever (body temperature > 37.5 ℃) after signing the consent, and before the endoscopic operation.
  3. Transferred to other department for additional treatment after the endoscopic operation (Surgical department for malignant tumor, Interventional radiology department for splenic embolism or transjugular intrahepatic portosystemic shunt, etc.).
  4. The patient suffered massive bleeding during the endoscopy, and cephalosporin was given immediately after being sent back to the ward.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

226 participants in 2 patient groups

Prophylactic antibiotics
Active Comparator group
Description:
Intravenous infusion of 1.0g-2.0g ceftriaxone before endoscopic therapy
Treatment:
Drug: Prophylactic Antibiotics
No prophylactic antibiotics
Experimental group
Description:
No use of prophylactic antibiotics before endoscopic therapy
Treatment:
Other: No use of prophylactic antibiotics

Trial contacts and locations

1

Loading...

Central trial contact

Meng Xue, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems